CompletedPHASE1, PHASE2NCT00631878
Safety and Pharmacokinetics Study in VLBW Neonates With BSYX-A110
Studying Staphylococcal toxemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Biosynexus Incorporated
- Principal Investigator
- Leonard Weisman, MDBaylor College of Medicine
- Intervention
- Pagibaximab (formerly BSYX-A110)(drug)
- Enrollment
- 53 target
- Eligibility
- All sexes
- Timeline
- 2001 – 2003
Study locations (1)
- Baylor College of Medicine, Houston, Texas, United States
Collaborators
GlaxoSmithKline
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00631878 on ClinicalTrials.govOther trials for Staphylococcal toxemia
Additional recruiting or active studies for the same condition.